{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.0","upperLimit":"113.0","value":"1.0"},{"groupId":"OG001","lowerLimit":"1.0","upperLimit":"108.0","value":"6.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"96"}],"units":"Participants"}],"description":"Time from first dose to first onset of achieving modified HI-E.\n\nThe modified HI-E criteria per the International Working Group (IWG) sustained over any consecutive 56-day period in Week 1-24: For participants with baseline red blood cell (RBC) transfusion burden of \\>= 4 units/8 weeks, a reduction of at least 4 units RBC transfusion; for participants with baseline RBC transfusion burden of \\< 4 units/8 weeks, mean increase of hemoglobin of at least 1.5 g/dL in the absence of transfusions.","dispersionType":"Full Range","groups":[{"description":"Starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks (21 days; Q3W). Dose levels can be increased in a stepwise manner beyond the starting dose to 1.33 mg/kg, and up to a maximum of 1.75 mg/kg.","id":"OG000","title":"Luspatercept"},{"description":"Starting dose of 450 IU/kg (maximum total starting dose is 40,000 IU) subcutaneous injection once every week (7 days; QW). Dose levels can be increased in a stepwise manner beyond the starting dose to 787.5 IU/kg, and up to a maximum of 1,050 IU/kg (with a maximum total dose of 80,000 IU).","id":"OG001","title":"Epoetin Alfa"}],"paramType":"MEDIAN","populationDescription":"ITT Population (all randomized participants regardless of whether or not the participant received treatment) who achieve HI-E response (Week 1-24)","reportingStatus":"POSTED","timeFrame":"Week 1 through Week 24","title":"Time to Hematologic Improvement - Erythroid Response (HI-E)","type":"SECONDARY","unitOfMeasure":"Days"}